Passive lung-targeted drug delivery systems via intravenous administration

References

• Chen JH, Wang L, Ling R, et al. Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig Dis Sci 2004;49:1170–3
   PubMed Web of Science ®Google Scholar
• Green MR, Manikhas GM, Orlov S, et al. Abraxane®, a novel Cremophor®-free, albuminbound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17:1263–8
   PubMed Web of Science ®Google Scholar
• Leucuta SE, Achim M, Risca R, Postescu ID. Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. Stp Pharm Sci 2003;13:291–7
   Google Scholar
• Santhi K, Dhanaraj SA, Koshy M, et al. Study of biodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm 2000;26:1293–6
   PubMed Web of Science ®Google Scholar
• Teng KY, Lu Z, Wientjes MG, Au JLS. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22:867–74
   PubMedGoogle Scholar
• Dailey LA, Kleemann E, Wittmar M, et al. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 2003;20:2011–20
   PubMed Web of Science ®Google Scholar
• McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006;23:901–11
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981–6
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85:227–34
   PubMed Web of Science ®Google Scholar
• Videira MA, Botelho MF, Santos AC, et al. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002;10:607–13
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Kuno Y, Sugimoto S, et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:373–81
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Eynott PR, Döring F, et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax 2002;57:55–60
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Witt C, Wagner U, et al. Fundamentals of pulmonary drug delivery. Resp Med 2003;97:382–7
   PubMed Web of Science ®Google Scholar
• Ana G, Begona S, Carmen RL. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005;25:427–37
   PubMedGoogle Scholar
• Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005;25:427–37
   PubMed Web of Science ®Google Scholar
• Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 2002;22:71S–9S
   PubMed Web of Science ®Google Scholar
• Gessler T, Schmehl T, Olschewski H, et al. Aerosolized vasodilators in pulmonary hypertension. J Aerosol Med 2002;15:117–22
   PubMedGoogle Scholar
• Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv 2008;21:1–12
   PubMedGoogle Scholar
• Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006;58:1061–75
   PubMed Web of Science ®Google Scholar
• Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781–801
   PubMed Web of Science ®Google Scholar
• Shirzad A, Wilson HR, Raimar L. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008;60:863–75
   PubMedGoogle Scholar
• Huynh GH, Deen DF, Szoka Jr FC. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 2006;110:236–59
   PubMed Web of Science ®Google Scholar
• Chao P, Deshmukh M, Kutscher HL, et al. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs 2010;21:65–76
   PubMed Web of Science ®Google Scholar
• Kutscher HL, Chao P, Deshmukh M, et al. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release 2010;143:31–7
   PubMed Web of Science ®Google Scholar
• Wattendorf U, Merkle HP. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J Pharm Sci 2008;97:3655–69
   Google Scholar
• Zhang L, Zeng PY, Pan J, Lu WY. Optimized formulation and preparation process of LFY calcium alginate lung targeting microspheres. Chin J Pharmaceuticals 2004;35:150–3
   Google Scholar
• Huo DJ, Deng SH, Li LB, Ji J. Studies on the poly(lactic-coglycolic) acid microspheres of cisplatin for lung targeting. Int J Pharm 2005;289:63–7
   PubMed Web of Science ®Google Scholar
• Lu B, Zhang JQ, Yang H. Lung-targeting microspheres of carboplatin. Int J Pharm 2003;265:1–11
   PubMed Web of Science ®Google Scholar
• Hao ZH, Qu BH, Wang YL, et al. Preparation and characterization of lung-targeting ceftiofur-loaded gelatin microspheres. Drug Dev Ind Pharm 2011;37:1422–8
   PubMed Web of Science ®Google Scholar
• Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001;205:1–7
   PubMed Web of Science ®Google Scholar
• Yang F, Wu SG, Pan YF, et al. Preparation and characteristics of erythromycin microspheres for lung targeting microspheres of erythromycin for lung targeting. Drug Dev Ind Pharm 2009;35: 639–45
   PubMedGoogle Scholar
• Tang S, Zhou Y, Li R, et al. Pharmacokinetics and lung-targeting characterization of a newly formulated enrofloxacin preparation. J vet Pharmacol Therap 2007;30:443–50
   PubMed Web of Science ®Google Scholar
• Sree H, Chandramouli R, Shobha R. Ofloxacin targeting to lungs by way of microspheres. Int J Pharm 2009;380:127–32
   PubMedGoogle Scholar
• Yan Z, Pei YY. Preparation, in vitro and in vivo evaluation of actively lung targetable microspheres for paclitaxel delivery. Chinese J Clin Pharm 2006;15:226–31
   Google Scholar
• Ying Y, Zhou SW, Tang JL, et al. Preparation of carboplatin microcapsules and tissue distribution in mice. China Pharmacy 2007;18:28–30
   Google Scholar
• Guo ZY, Zhao Wj, Zhang Q. Preparation and evaluation of lung targeting microspheres for protionamide in vitro and in vivo. Tuber Thor Tumor 2011;1:19–24
   Google Scholar
• Zhan ZJ, Fan CQ, Ding J, Yue JM. Novel diterpenoids with potent inhibitory activity against endothelium cell HMEC and cytotoxic activities from a well-known TCM plant Daphne genkwa. Bioorg Med Chem 2005;13:645–55
   PubMed Web of Science ®Google Scholar
• Zhang SX, Li XN, Zhang FH, et al. Preparation of yuanhuacine and relative daphne diterpeneesters from Daphne genkwa and structure-activity relationship of potent inhibitory activity against DNA topoisomerase I. Bioorg Med Chem 2006;14:3888–95
   PubMed Web of Science ®Google Scholar
• Park BY, Min BS, Ahn KS, et al. Daphnane diterpene esters isolated from flower buds of Daphne genkwa induce apoptosis in human myelocytic HL-60 cells and suppress tumor growth in Lewis lung carcinoma (LLC)-inoculated mouse model. J Ethnopharmacol 2007;111:496–503
   PubMed Web of Science ®Google Scholar
• Zhang SX, Gao XJ, Shen KH, et al. Evaluation of poly(d,l-lactide-co-glycolide) microspheres for the lung-targeting of yuanhuacine, a novel DNA topoisomerase I inhibitor. J Drug Target 2009;17:286–93
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002;79:29–40
   PubMed Web of Science ®Google Scholar
• Kutscher HL, Chao P, Deshmukh M, et al. Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int J Pharm 2010;402:64–71
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505–15
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4:297–305
   PubMedGoogle Scholar
• Waser PG, Muller U, Kreuter J, et al. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradigraphy in mice. Int J Pharm 1987;39:213–27
   Web of Science ®Google Scholar
• Zhang XK, Sun P, Bi R, et al. Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation. J Drug Target 2009;17:399–407
   PubMed Web of Science ®Google Scholar
• Kusmic C, Picano E, Busceti CL, et al. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc Res 2000;47:510–14
   PubMed Web of Science ®Google Scholar
• Cheng JI, Wen NA, Xiong F, et al. Characterization, lung targeting profile and therapeutic efficiency of dipyridamole liposomes. J Drug Target 2006;14:717–24
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch 2006;50:2946–50
   PubMed Web of Science ®Google Scholar
• Rodríguez-Hernández MJ, Saugar J, Docobo-Pérez F, et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Ch 2006;58:95–100
   PubMed Web of Science ®Google Scholar
• Tewes F, Brillault J, Couet W, Olivier JC. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J Control Release 2008;129:93–9
   PubMed Web of Science ®Google Scholar
• Jiang QJ, Geng F, Zhang W. DepoFoam loading GD-DTPA targeting to lung: animal studies. Chinese J Oncoradiology 2009;2:25–9
   Google Scholar
• Hirano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci 1985;74:915–21
   PubMed Web of Science ®Google Scholar
• Sada E, Kato S, Terashima M, Kawahara H. Effects of surface charges and cholesterol content on aminoacid permeabilities of small unilamllar vesicles. J Pharm Sci 1990;79:232–5
   PubMed Web of Science ®Google Scholar
• Abra RM, Hunt CA, Lau DT. Liposome disposition in vivo. VI: Delivery to the lung. J Pharm Sci 1984;73:203–6
   PubMed Web of Science ®Google Scholar
• Kim CK, Lee MK, Han JH, Lee BJ. Pharmacokinetics and tissue distribution of methotrexate after intravenous injection of differently charged liposome-entrapped methotrexate to rats. Int J Pharm 1994;108:21–9
   Web of Science ®Google Scholar
• Jonah MM, Cerny EA, Rahman YE. Tissue distribution of EDTA encapsulated within liposomes of varying surface properties. Biochim Biophys Acta 1975;401:336–48
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu JB, Shen W. Preparation of lung targeting azithromycin liposomes and its tissue distribution in mice. Acta Pharmaceutica Sinica 2005;40:274–8
   PubMedGoogle Scholar
• Zhao L, Ye Y, Li J, Wei YM. Preparation and the in vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. J Pharm Pharmacol 2011;63:80–6
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei YM, Zhong XD, et al. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 2009;49:989–96
   PubMed Web of Science ®Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007;96:203–9
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei YM, Li W, et al. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and vivo evaluation. J Drug Target 2011;19:171–8
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451–8
   PubMed Web of Science ®Google Scholar
• Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029–46
   PubMed Web of Science ®Google Scholar
• Betancourt T, Brown B, Peppas LB. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007;2:219–32
   PubMed Web of Science ®Google Scholar
• Lowery AR, Gobin AM, Day ES, et al. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomed 2006;1:149–54
   PubMed Web of Science ®Google Scholar
• Flenniken ML, Liepold LO, Crowley BE, et al. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun 2005;28:447–9
   Google Scholar
• Xiang QY, Wang MT, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007;30:519–25
   PubMed Web of Science ®Google Scholar
• Zhu L, Jia X, A YM, Zhang ZZ. In vivo distribution of gatifloxacin polybutylcyanoacrylate nanoparticles in mice. Chin J New Drugs 2010;19:60–3
   Google Scholar
• Shi Y, He F, Huang C, Tan ZN. Preparation and distribution in mice of itraconazole nanoparticles. Chin J Pharma 2010;41:106–10
   Google Scholar